<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01342679</url>
  </required_header>
  <id_info>
    <org_study_id>KCSG-02</org_study_id>
    <nct_id>NCT01342679</nct_id>
  </id_info>
  <brief_title>A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib</brief_title>
  <acronym>CMR-CML</acronym>
  <official_title>A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanto CML Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Epidemiological and Clinical Research Information Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kanto CML Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate complete molecular response of Dasatinib in patients
      for Philadelphia chromosome-positive chronic myeloid leukemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete molecular response (CMR) after treatment with dasatinib</measure>
    <time_frame>at 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dasatinib of dose intensity</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansions rate of large granular lymphocyte</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>dasatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <description>100mg QD</description>
    <arm_group_label>dasatinib</arm_group_label>
    <other_name>BMS-354825</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic Myeloid Leukemia in the Chronic Phase

          -  20 years old over

          -  ECOG performance status (PS) score 0-2

          -  Patients for major molecular response (MMR) with no CMR

          -  Adequate organ function (hepatic, renal and lung)

          -  Signed written informed consent

        Exclusion Criteria:

          -  A case with the double cancer of the activity

          -  Women who are pregnant or breastfeeding

          -  The case of Pleural effusion clearly

          -  Patients with complications or a history of severe or uncontrolled cardiovascular
             failure following

               -  have a Myocardial infarction within 6 months

               -  have an Angina within 3 months

               -  have a Congestive heart failure within 3 months

               -  have a suspected congenital QT syndrome

               -  have a QTc interval of more than 450msec at baseline

          -  A serious uncontrolled medical disorder that would impair the ability of the subjects
             to receive protocol therapy

          -  Prior treatment with dasatinib

          -  Subjects with T315I, F317L and V299L BCR-ABL point mutations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chikashi Yoshida, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Hospital Organization, Mito Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2011</study_first_submitted>
  <study_first_submitted_qc>April 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2011</study_first_posted>
  <last_update_submitted>September 14, 2015</last_update_submitted>
  <last_update_submitted_qc>September 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2015</last_update_posted>
  <responsible_party>
    <name_title>Hisashi Sakamaki</name_title>
    <organization>Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital</organization>
  </responsible_party>
  <keyword>chronic myeloid leukemia</keyword>
  <keyword>dasatinib</keyword>
  <keyword>complete molecular response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

